BUSINESS
Otsuka/Taiho Look to Leverage Araris’ Linker Tech to Create 1st-in-Class ADCs
Taiho Pharmaceutical, an Otsuka Holdings company, intends to develop first-in-class antibody drug conjugates (ADCs) through the acquisition of Swiss ADC specialist Araris Biotech, which has a linker technology proven to boost the safety and efficacy of conjugated compounds. President Masayuki…
To read the full story
Related Article
- Taiho Picks Up Araris, Bagging 3 Key Preclinical ADCs
March 18, 2025
BUSINESS
- Pharma Hails End to “Spillover” Rule, Vows to Keep Fighting Off-Year Cuts
December 25, 2025
- Drug Wholesalers Slam “No-Discussion” Decision on FY2027 Off-Year Price Revision
December 25, 2025
- JCR Earns Japan Rights to DMD Drug from Italfarmaco
December 25, 2025
- Fujifilm Completes Major Biologics CDMO Plant in Toyama, Eyes 2027 Start-Up
December 25, 2025
- Alfresa’s Cell Resources Inks Partnership with Korea’s ENCell
December 25, 2025
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…





